Alzheimer's disease: Clinical trials to watch.

Authors

Marwan Noel Sabbagh, Jessica Kennedy, Jad Majeed, Boris Decourt

Published in

Med (New York, N.Y.). Volume 6. Issue 8. Pages 100771. Aug 08, 2025.

Abstract

Second-generation anti-amyloid therapies (ATTs) offer new options for early Alzheimer's disease treatment, but with modest efficacy and documented adverse events. Here we highlight several ongoing clinical trials, aiming to develop therapeutic agents with higher efficacy and better safety profiles including third-generation ATTs, aggregation inhibitors, Sigma-1 receptor agonists, anti-tau antisense oligonucleotides, and GLP-1 receptor agonists.

PMID:
40782673
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.